Severe erythrodermic psoriasis, unresponsive to systemic treatments, is disabling for the patient and a challenge for dermatologists. Methotrexate, cyclosporine, and acitretin have been the treatments of choice.1 However, long-term therapy with these drugs often leads to difficult complications or adverse effects. Thus, new biologic agents such as tumor necrosis factor (TNF) inhibitors provide a welcome alternative. In controlled clinical trials, infliximab has proven to be an effective and fast-acting treatment for plaque-type psoriasis.2- 4
Heikkilä H, Ranki A, Cajanus S, Karvonen S. Infliximab Combined With Methotrexate as Long-term Treatment for Erythrodermic Psoriasis. Arch Dermatol. 2005;141(12):1607–1610. doi:10.1001/archderm.141.12.1607
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.